Compositions comprising transforming growth factor (TGF)-β1 and TGF-β2 in admixture of proteins obtained from dairy products

Abstract

The present invention relates to a composition and methods or uses thereof in the prophylaxis and treatment of psoriasis and other auto-immune inflammatory disorders. The composition may be comprised of TGF-β1, TGF-β2, and dairy derived proteins comprising a large proportion of β-lactoglobulin.

1. A composition comprising Transforming Growth Factor (TGF)-β1 and TGF-β2, in admixture with proteins, wherein said TGF-β1 is at a concentration between 0.01 to 5 μg/g of the composition, said TGF-β2 is at a concentration between 5 to 50 μg/g of the composition, and said proteins are present in a concentration of at least 15% (w/w) of the composition and said proteins comprise at least 30% of β-lactoglobulin and less than 25% α-lactalbumin, wherein said TGF-β1, TGF-β2, proteins, β-lactoglobulin and α-lactalbumin are obtained from a single source of dairy product. 
     
     
       2. The composition of  claim 1 , wherein said proteins are present at a concentration of at least 50% (w/w), and comprises at least 60% of β-lactoglobulin. 
     
     
       3. The composition of  claim 1 , wherein said TGF-β1 is at a concentration between 0.1 to 5 μg/g of the composition. 
     
     
       4. The composition of  claim 3 , wherein said TGF-β1 is at a concentration between 0.2 to 1.2 μg/g of the composition. 
     
     
       5. The composition of  claim 1 , wherein said TGF-β2 is at a concentration between 8 to 20 μg per gram of the composition. 
     
     
       6. The composition of  claim 5 , wherein said TGF-β2 is at a concentration between 10 to 18 μg per gram of the composition. 
     
     
       7. The composition of  claim 1 , wherein said proteins obtained from dairy products are at a concentration of at least 80% (w/w) of the composition. 
     
     
       8. The composition of  claim 1 , comprising 0.1 to 15% (w/w) of minerals. 
     
     
       9. The composition of  claim 1 , further comprising Insulin-like Growth Factor-1 (IGF-1) obtained from the same source of dairy products as in  claim 1 . 
     
     
       10. The composition of  claim 9 , wherein said Insulin-like Growth Factor-1 (IGF-1) is at a concentration between 0.01 to 2 μg/g of the composition. 
     
     
       11. A method for the treatment of psoriasis comprising the step of: administering to a patient in need thereof a composition comprising: Transforming Growth Factor (TGF)-β1, TGF-β2, in admixture with proteins obtained from dairy products with a total protein concentration of at least 15% (w/w), wherein said TGF-β1 is at a concentration between 0.01 to 5 μg/g of composition, said TGF-β2 is at a concentration between 5 to 50 μg/g of composition, and said proteins obtained from dairy products contain at least 30% of β-lactoglobulin. 
     
     
       12. The method of treatment of  claim 11 , wherein said proteins obtained from dairy products are at a total protein concentration of at least 50% (w/w), and comprises at least 60% of β-lactoglobulin. 
     
     
       13. The method of treatment according to  claim 11 , wherein said TGF-β1 is at a concentration between 0.1 to 5 μg/g of composition. 
     
     
       14. The method of treatment according to  claim 13 , wherein said TGF-β1 is at a concentration between 0.2 to 1.2 μg/g of composition. 
     
     
       15. The method of treatment according to  claim 11 , wherein said TGF-β2 is at a concentration between 8 to 20 μg per gram of composition. 
     
     
       16. The method of treatment according to  claim 14 , wherein said TGF-β2 is at a concentration between 10 to 18 μg per gram of composition. 
     
     
       17. The method of treatment according to  claim 11 , wherein said dairy proteins are at a concentration of at least 80% (w/w) of the composition. 
     
     
       18. The method of treatment according to  claim 11 , comprising 0.1 to 15% (w/w) of minerals. 
     
     
       19. The method of treatment according to  claim 11 , wherein said TGF-β1 and said TGF-γ2 are derived from dairy products. 
     
     
       20. The method of treatment according to  claim 11 , further comprising Insulin-like Growth Factor-1 (IGF-1) derived from dairy products. 
     
     
       21. The method of treatment according to  claim 19 , wherein said Insulin-like Growth Factor-1 (IGF-1) is at a concentration between 0.01 to 2 μg/g of composition. 
     
     
       22. The composition of  claim 1  or  9 , wherein said dairy product is whey.